FY2024 Earnings Estimate for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Research analysts at HC Wainwright dropped their FY2024 earnings per share estimates for Invivyd in a report issued on Wednesday, November 20th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($1.63) for the year, down from their prior estimate of ($1.15). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($0.90) per share. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.

Several other brokerages also recently issued reports on IVVD. Morgan Stanley cut their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th.

Invivyd Stock Performance

Invivyd stock opened at $0.70 on Friday. Invivyd has a 52 week low of $0.70 and a 52 week high of $5.20. The stock has a market capitalization of $83.71 million, a P/E ratio of -0.36 and a beta of 0.65. The stock has a 50-day simple moving average of $0.97 and a 200 day simple moving average of $1.25.

Institutional Trading of Invivyd

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after buying an additional 97,496 shares during the last quarter. State Street Corp grew its stake in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Finally, Duquesne Family Office LLC bought a new stake in shares of Invivyd in the second quarter worth $629,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.